{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:57:19Z","timestamp":1774724239151,"version":"3.50.1"},"reference-count":44,"publisher":"The Society for Free Radical Research Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2025]]},"DOI":"10.3164\/jcbn.25-68","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:09:34Z","timestamp":1751393374000},"page":"203-208","source":"Crossref","is-referenced-by-count":3,"title":["Targeting &lt;i&gt;Helicobacter pylori&lt;\/i&gt; in liver-impaired populations: a systematic review of efficacy and safety"],"prefix":"10.3164","volume":"77","author":[{"given":"Hideki","family":"Mori","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Iino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology, Graduate School of Medicine, Hirosaki University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fujieda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kitaibaraki City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Malfertheiner P, Megraud F, Rokkas T, et al. Management of <i>Helicobacter pylori<\/i> infection: the Maastricht VI\/Florence consensus report. Gut 2022; 71: 1724\u20131762.","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kato M, Ota H, Okuda M, et al. Guidelines for the management of <i>Helicobacter pylori<\/i> infection in Japan: 2016 revised edition. Helicobacter 2019; 24: e12597.","DOI":"10.1111\/hel.12597"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Mori H, Suzuki H. Update on quinolone-containing rescue therapies for <i>Helicobacter pylori<\/i> infection. World J Gastroenterol 2020; 26: 1733\u20131744.","DOI":"10.3748\/wjg.v26.i15.1733"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mori H, Suzuki H, Omata F, et al. Current status of first- and second-line <i>Helicobacter pylori<\/i> eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol 2019; 12: 1756284819858511.","DOI":"10.1177\/1756284819858511"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Antibiotic resistance and <i>gyrA<\/i> mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for <i>Helicobacter pylori<\/i> in penicillin allergic patients. United European Gastroenterol J 2017; 5: 796\u2013804.","DOI":"10.1177\/2050640616688995"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for <i>Helicobacter pylori<\/i> Infection. Gastroenterol Clin North Am 2010; 39: 465\u2013480.","DOI":"10.1016\/j.gtc.2010.08.007"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Furuta T, Sugimoto M, Kodaira C, et al. Personalized medicine for eradication of <i>Helicobacter pylori<\/i>. Per Med 2007; 4: 321\u2013328.","DOI":"10.2217\/17410541.4.3.321"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. 10-Year trends in <i>Helicobacter pylori<\/i> eradication rates by sitafloxacin-based third-line rescue therapy. Digestion 2020; 101: 644\u2013650.","DOI":"10.1159\/000501610"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","DOI":"10.1136\/bmj.n71"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Nishizawa T, Suzuki H, Akimoto T, et al. Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: a systematic review and meta-analysis. United European Gastroenterol J 2016; 4: 5\u201310.","DOI":"10.1177\/2050640615588023"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol 2014; 14: 45.","DOI":"10.1186\/1471-2288-14-45"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Chang SS, Hu HY. Early <i>Helicobacter pylori<\/i> eradication is associated with a reduced risk of recurrent peptic ulcers in cirrhotic patients. J Dig Dis 2014; 15: 451\u2013458.","DOI":"10.1111\/1751-2980.12159"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Zhang XH, He Y, Feng R, et al. <i>Helicobacter pylori<\/i> infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: a multicenter, observational study. Platelets 2016; 27: 223\u2013229.","DOI":"10.3109\/09537104.2015.1077946"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Schulz C, Sch\u00fctte K, Malfertheiner P. Does <i>H. pylori<\/i> eradication therapy benefit patients with hepatic encephalopathy?: systematic review. J Clin Gastroenterol 2014; 48: 491\u2013499.","DOI":"10.1097\/MCG.0000000000000108"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Zullo A, Hassan C, Morini S. <i>Helicobacter pylori<\/i> infection in patients with liver cirrhosis: facts and fictions. Dig Liver Dis 2003; 35: 197\u2013205.","DOI":"10.1016\/S1590-8658(03)00029-X"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Zullo A, Cristofari F, Hassan C. <i>H. pylori<\/i> should be eradicated in chronic liver disease patients with peptic ulcer. Dig Liver Dis 2009; 41: 141\u2013142.","DOI":"10.1016\/j.dld.2008.11.004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Polyzos SA, Kountouras J. <i>Helicobacter pylori<\/i> infection and nonalcoholic fatty liver disease: time for large clinical trials evaluating eradication therapy. Helicobacter 2019; 24: e12588.","DOI":"10.1111\/hel.12588"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Li J, Yu H, Wang Y, et al. A meta-analysis of the association between <i>Helicobacter pylori<\/i> infection and risk of hepatic encephalopathy. J Public Health (Oxf) 2023; 45: 321\u2013329.","DOI":"10.1093\/pubmed\/fdac078"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Tsai CE, Liang CM, Lee CH, et al. First-line <i>Helicobacter pylori<\/i> eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci 2016; 32: 397\u2013402.","DOI":"10.1016\/j.kjms.2016.05.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Jung SW, Lee SW, Hyun JJ, et al. Efficacy of <i>Helicobacter pylori<\/i> eradication therapy in chronic liver disease. Dig Liver Dis 2009; 41: 134\u2013140.","DOI":"10.1016\/j.dld.2008.03.005"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Azuma T, Ito S, Suto H, et al. Pharmacokinetics of clarithromycin in <i>Helicobacter pylori<\/i> eradication therapy in patients with liver cirrhosis. Aliment Pharmacol Ther 2000; 14 Suppl 1: 216\u2013222.","DOI":"10.1046\/j.1365-2036.2000.014s1216.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Furusyo N, Walaa AH, Eiraku K, et al. Treatment for eradication of <i>Helicobacter pylori<\/i> infection among chronic hepatitis C patients. Gut Liver 2011; 5: 447\u2013453.","DOI":"10.5009\/gnl.2011.5.4.447"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of <i>Helicobacter pylori<\/i> eradication on liver fat content in subjects with non-alcoholic fatty liver disease: a randomized open-label clinical trial. Hepat Mon 2013; 13: e14679.","DOI":"10.5812\/hepatmon.14679"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Yu YY, Tong YL, Wu LY, Yu XY. <i>Helicobacter pylori<\/i> infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep 2022; 12: 19530.","DOI":"10.1038\/s41598-022-23746-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Jamali A, Karbalai S, Tefagh G, Jamali R, Ahmadi A. The effects of <i>Helicobacter pylori<\/i> eradication on liver function and metabolic profile in non-diabetic non-alcoholic steatohepatitis: a 5-year randomized clinical trial. Middle East J Dig Dis 2022; 14: 85\u201395.","DOI":"10.34172\/mejdd.2022.260"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Chen SJ, Wang LJ, Zhu Q, Cai JT, Chen T, Si JM. Effect of <i>H pylori<\/i> infection and its eradication on hyperammonemia and hepatic encephalopathy in cirrhotic patients. World J Gastroenterol 2008; 14: 1914\u20131918.","DOI":"10.3748\/wjg.14.1914"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Hanafy AS, El Hawary AT, Hamed EF, Hassaneen AM. Impact of <i>Helicobacter pylori<\/i> eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy. Eur J Clin Microbiol Infect Dis 2016; 35: 1171\u20131176.","DOI":"10.1007\/s10096-016-2650-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Takashima T, Enomoto H, Iwata Y, et al. Effects of <i>Helicobacter pylori<\/i> eradication on the platelet count in hepatitis C virus-infected patients. J Clin Med Res 2016; 8: 854\u2013858.","DOI":"10.14740\/jocmr2725w"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181\u2013202.","DOI":"10.1517\/phgs.5.2.181.27483"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Yamasaki H, Kawaguchi N, Nonaka M, et al. <i>In vitro<\/i> metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica 2017; 47: 1027\u20131034.","DOI":"10.1080\/00498254.2016.1203505"},{"key":"32","unstructured":"32 Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC. <i>In vivo<\/i> effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 2001; 29: 1023\u20131028."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Pearce RE, Cohen-Wolkowiez M, Sampson MR, Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos 2013; 41: 1686\u20131694.","DOI":"10.1124\/dmd.113.052548"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil 2019; 25: 6\u201314.","DOI":"10.5056\/jnm18139"},{"key":"35","unstructured":"35 Perl\u00edk F. Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs. Vnitr Lek 2013; 59: 584\u2013586. (in Czech)"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Villeneuve JP, Fortunet-Fouin H, Ars\u00e8ne D. Cimetidine kinetics and dynamics in patients with severe liver disease. Hepatology 1983; 3: 923\u2013927.","DOI":"10.1002\/hep.1840030606"},{"key":"37","unstructured":"37 Zhao JR, Wang JY, Li SL. <i>Helicobacter pylori<\/i> and hepatic encephalopathy. Zhonghua Gan Zang Bing Za Zhi 2018; 26: 553\u2013556. (in Chinese)"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of <i>Helicobacter pylori<\/i> infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 2001; 115: 1002\u20131003.","DOI":"10.1046\/j.1365-2141.2001.03194.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5: 8096.","DOI":"10.1038\/srep08096"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Tarantino G, Cataldi M, Citro V. Could chronic opioid use be an additional risk of hepatic damage in patients with previous liver diseases, and what is the role of microbiome? Front Microbiol 2024; 15: 1319897.","DOI":"10.3389\/fmicb.2024.1319897"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Schoenaker JM, Nelson VS, Henderickx JGE, et al. The intestinal flora: the key to unraveling heterogeneity in immune thrombocytopenia? Blood Rev 2025; 69: 101252.","DOI":"10.1016\/j.blre.2024.101252"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Wang JG, Dou HH, Liang QY. Impact of gut microbiota and inflammatory cytokines on immune thrombocytopenia. Eur J Haematol 2025; 114: 120\u2013128.","DOI":"10.1111\/ejh.14310"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542\u20131556.","DOI":"10.1097\/HEP.0000000000000696"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol 2024; 80: 694\u2013701.","DOI":"10.1016\/j.jhep.2024.01.014"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/77\/3\/77_25-68\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:08:58Z","timestamp":1761970138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/77\/3\/77_25-68\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.25-68","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25-68"}}